September 24, 2018
Just days after California regulators accused AbbVie Inc. of engaging in a massive kickback scheme that tainted $1.3 billion in insurance claims for its blockbuster immunosuppressant Humira, investors followed up with a potential class action accusing the drugmaker of defrauding them as well.